TMCnet News
Research and Markets: Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H2, 2014DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/54kft4/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H2, 2014" report to their offering. Our clinical trial report, Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H2, 2014" provides data on the Relapsing Remitting Multiple Sclerosis (RRMS) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsing Remitting Multiple Sclerosis (RRMS). It includes an overview of the trial numbers and their recruitment status as perthe site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsing Remitting Multiple Sclerosis (RRMS). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope
Reasons to buy
For more information visit http://www.researchandmarkets.com/research/54kft4/relapsing
|